PAX Stock Overview
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Paxman AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr36.30 |
52 Week High | kr39.70 |
52 Week Low | kr22.00 |
Beta | 0.72 |
1 Month Change | -2.16% |
3 Month Change | 0% |
1 Year Change | 8.36% |
3 Year Change | -27.40% |
5 Year Change | -18.79% |
Change since IPO | 233.03% |
Recent News & Updates
Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Dec 23Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue
Aug 25Recent updates
Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Dec 23Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue
Aug 25Paxman AB (publ) (STO:PAX) Could Be Riskier Than It Looks
Jun 01Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Nov 20Is Paxman (STO:PAX) A Risky Investment?
Mar 07Paxman (STO:PAX) Is Making Moderate Use Of Debt
Mar 15Are Insiders Buying Paxman AB (publ) (STO:PAX) Stock?
Jan 22Reflecting on Paxman's (STO:PAX) Share Price Returns Over The Last Year
Dec 18Shareholder Returns
PAX | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | 5.2% | 0.5% | 1.8% |
1Y | 8.4% | -3.9% | 19.0% |
Return vs Industry: PAX exceeded the Swedish Medical Equipment industry which returned -3.9% over the past year.
Return vs Market: PAX underperformed the Swedish Market which returned 19% over the past year.
Price Volatility
PAX volatility | |
---|---|
PAX Average Weekly Movement | 4.2% |
Medical Equipment Industry Average Movement | 8.1% |
Market Average Movement | 6.0% |
10% most volatile stocks in SE Market | 12.7% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: PAX has not had significant price volatility in the past 3 months.
Volatility Over Time: PAX's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 91 | Richard Paxman | https://paxmanscalpcooling.com |
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various clinics and treatment centers, and hospitals. The company has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device.
Paxman AB (publ) Fundamentals Summary
PAX fundamental statistics | |
---|---|
Market cap | kr690.15m |
Earnings (TTM) | kr8.24m |
Revenue (TTM) | kr220.61m |
83.8x
P/E Ratio3.1x
P/S RatioIs PAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PAX income statement (TTM) | |
---|---|
Revenue | kr220.61m |
Cost of Revenue | kr74.19m |
Gross Profit | kr146.42m |
Other Expenses | kr138.18m |
Earnings | kr8.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
Earnings per share (EPS) | 0.43 |
Gross Margin | 66.37% |
Net Profit Margin | 3.73% |
Debt/Equity Ratio | 11.1% |
How did PAX perform over the long term?
See historical performance and comparison